Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian Cancer

Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.

Kathleen Moore, MD, associate director of clinical research at the Stephenson Cancer Center at the University of Oklahoma, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha (FRα)—positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.

The phase III findings demonstrated that the antibody—drug conjugate had a very differentiated safety profile with no new safety signals. There were far fewer grade 3 treatment-emergent adverse events (TRAEs) and patients requiring dose reduction due to TRAEs, Moore notes. There were also very low rates of treatment discontinuation due to toxicity in both arms of the trial.

There was statistically less hematologic toxicities and less neuropathy. Moore adds that there was no alopecia, and the toxicity profile was as expected, with low-grade nausea, diarrhea, and visual disturbances, which were all mitigated with preplanned interventions.

In the primary analysis of progression-free survival (PFS), there were no differences between arms. The median PFS was 3.39 months in the control arm, as expected, while patients in the FRα-high subpopulation had a median PFS of 4.6 months with aP